MICROSUL Drug Patent Profile

When do Microsul patents expire, and when can generic versions of Microsul launch?

Microsul is a drug marketed by Forest Pharms and is included in one NDA.

The generic ingredient in MICROSUL is sulfamethizole. There are four drug master file entries for this compound. Additional details are available on the sulfamethizole profile page.

Summary for MICROSUL

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	5,579
DailyMed Link:	MICROSUL at DailyMed

US Patents and Regulatory Information for MICROSUL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Forest Pharms	MICROSUL	sulfamethizole	TABLET;ORAL	086012-001	Approved Prior to Jan 1, 1982		DISCN	No	No

MICROSUL (Micronized Sulfasalazine) Market Dynamics and Financial Trajectory: Uptake, Revenue Exposure, and Competitive Risk

Last updated: July 10, 2026

Executive summary: MICROSUL is a branded micronized sulfasalazine product in the US market. Its financial trajectory is constrained by a crowded, low-cost sulfasalazine generic landscape, limited differentiated IP (if any), and ongoing substitution pressure toward established generics and therapeutically substitutable 5-ASA and other anti-inflammatory regimens in ulcerative colitis (UC) and rheumatoid arthritis (RA). Without meaningful evidence of patent or regulatory exclusivity beyond core sulfasalazine supply, MICROSUL revenue growth depends primarily on (1) payer access and formulary placement, (2) milligram-to-therapeutic equivalence and tolerability narratives versus standard sulfasalazine, and (3) persistent demand in patient segments that perceive micronization as improving GI tolerability.

What is MICROSUL and where does it fit in the sulfasalazine market?

Quick answer: MICROSUL is a sulfasalazine brand positioned on micronization to support improved tolerability and usability versus conventional sulfasalazine formulations. Therapeutic demand tracks UC and RA prescribing and adherence patterns and payer incentives for generics.

Active ingredient, therapeutic category, and use profile

• Drug class: Sulfonamide anti-inflammatory (disease-modifying agent in RA; treatment for UC)
• Indications (typical):
  • Ulcerative colitis
  • Rheumatoid arthritis
• Mechanistic positioning in market narratives: Sulfasalazine efficacy derives from topical 5-ASA release and systemic anti-inflammatory effects; micronization is used to manage tolerability and dosing practicality.

Market structure for sulfasalazine

Sulfasalazine is a mature, generic-dominant market with entrenched channel relationships and price competition. Branded “line extensions” typically capture share through:

• patient switching from standard sulfasalazine where tolerability is perceived as better
• payer preference for specific NDCs within formularies where “micronized” is considered a distinct product
• distributor inventory and contract terms

If MICROSUL is not protected by strong, late-life exclusivity (formulation, method-of-use, or pediatric/conditional), long-run economics trend toward generic parity pricing and declining gross margin.

How do market dynamics shape MICROSUL pricing power and share?

Quick answer: MICROSUL pricing power is structurally limited by generic substitution. Its share sustainability depends on payer contracting and patient-level tolerability differentiation, not on durable patent leverage.

Generic substitution and class competition

Key pressures in sulfasalazine-driven products:

• Low switching costs to generic sulfasalazine tablets
• Therapeutic interchange within IBD and RA:
  • For UC: 5-ASA products (e.g., mesalamine formulations) and other anti-inflammatory options can compress sulfasalazine demand.
  • For RA: conventional synthetic DMARDs and biologics target the same treatment goals, shifting prescribing over time.
• Payer step therapy for RA and UC often favors lower cost DMARD/IBD therapies unless specific clinical rationales are documented.

Differentiation: micronization as a commercial lever

Micronization can be a meaningful micro-segment lever if it:

• reduces GI adverse events in practice
• improves adherence versus standard formulations
• supports claims around tolerability that can be coded in prior authorization and pharmacy benefit documentation

That differentiation typically does not prevent generic price erosion; it can slow it if payers treat the micronized product as functionally distinct in contracting.

Channel dynamics

Revenue outcomes are driven by:

• PBM formulary status (preferred vs non-preferred)
• rebate and contracting intensity versus generics
• WAC-to-net compression from typical branded rebate structures
• inventory cycles and distributor purchasing patterns, especially for mature molecules where customers hedge supply and price risk

When does MICROSUL face the biggest revenue risk from generics?

Quick answer: The biggest revenue risk is not a single expiration date but the persistent ability of generic manufacturers to supply therapeutically equivalent sulfasalazine at lower net pricing. Absent a robust, late-expiring exclusivity moat, MICROSUL’s revenue ceiling trends downward over time.

What determines the timing of revenue compression

Even without explicit patent cliffs, branded sulfasalazine product economics compress through:

• generic market share gains after formulary updates
• NDC switching by plan formularies that target price per day
• channel de-stocking when contracts re-price at renewal

In practice, revenue risk typically manifests in waves aligned with contract cycles rather than a single legal date.

What is the financial trajectory likely to look like for MICROSUL?

Quick answer: For mature sulfasalazine brands, the financial trajectory usually follows one of two paths:

1. stable low-growth revenue with margin pressure as branded accounts convert to generics
2. revenue decline when payer management accelerates substitution and contract terms shift

MICROSUL’s path depends on whether it has measurable clinical differentiators that survive payer scrutiny and whether it retains preferred positioning.

Revenue model drivers

For a branded mature therapy, revenue is a function of:

• TRx volume (patient base and prescribing rate)
• market share vs generic sulfasalazine
• net price after rebates and discounts
• persistent access (PBM utilization management)

Margin model drivers

For branded generics-adjacent products:

• rebate intensity rises as plans insist on price concessions
• sales and marketing must increase to defend share against low-cost competition
• manufacturing and distribution economics tighten as volumes flatten

If MICROSUL is priced materially above the generic baseline, net margin resilience depends on contracting leverage and brand-level value perception.

How strong is the patent estate and what does that imply for MICROSUL’s long-term economics?

Quick answer: The long-term economics for a mature sulfasalazine product are usually determined by whether MICROSUL has differentiated, enforceable IP beyond the base sulfasalazine compound. Without meaningful exclusivity, the brand’s long-run value depends on managed access rather than patent protection.

Patent estate mechanics that matter commercially

For a branded micronized formulation, commercially relevant IP would typically fall into:

• specific formulation composition or particle size range
• manufacturing method that achieves micronized characteristics
• method-of-use differentiating clinical outcomes
• combination products (less likely here given MICROSUL naming)

Absent those, the brand is economically exposed to generic substitution.

Orange Book and exclusivity angle

From a business perspective, investors and counsel typically key on:

• listed patents in FDA’s Orange Book
• expiration dates
• whether MICROSUL’s NDA/BLA has any 5-year/3-year exclusivity, pediatric exclusivity, or periods that extend differentiation

If the Orange Book listing is sparse or early-expiring, the commercial outlook trends toward conversion to lower-cost supply.

What generic entry risks exist for MICROSUL? (Paragraph IV and non-Paragraph IV scenarios)

Quick answer: In mature sulfasalazine, the generic entry risk is usually “process and price” rather than a Paragraph IV litigation event, unless MICROSUL has Orange Book-listed patents that support a filing requiring certification and potential litigation.

Two practical pathways for generic pressure

• Non-Paragraph IV: generic manufacturers file based on lack of listed exclusivity or after listed patents expire
• Paragraph IV: if Orange Book patents exist, a generic can file with “asserted” non-infringement or invalidity positions, triggering a potential litigation and stay dynamic

What matters for MICROSUL cash-flow stability

• likelihood of successful FDA approval without forced launch delay
• settlement probability and typical structure (often supply and branding agreements rather than product redesign)
• strength of the patent claims relative to generic processes

How does MICROSUL compare with other UC and RA standard-of-care products on commercial positioning?

Quick answer: Sulfasalazine brands compete not only with generic sulfasalazine but also with 5-ASA products for UC and broader DMARD pipelines for RA. MICROSUL’s micronization advantage can help within the sulfasalazine niche but does not immunize against class switching.

UC competitive set

• 5-ASA oral agents and rectal agents compete on tolerability, dosing convenience, and payer preference
• biologics and small molecules can shift severe cases away from sulfasalazine over time

RA competitive set

• conventional DMARDs and newer targeted therapies reduce RA reliance on older sulfonamides
• payer policies tend to steer to lowest net cost effective options

Which companies are likely the MICROSUL competitive set in supply and contracting?

Quick answer: For MICROSUL specifically, the competitive set is the generic sulfasalazine supply base rather than a single branded rival. In practice, the relevant players are the manufacturers/distributors with scale and strong PBM contracting.

How to interpret “who matters” commercially

• PBM preferred-list suppliers
• top generic sulfasalazine manufacturers with high AR volume
• contract holders who can win dispensing economics at pharmacy counters

What FDA and labeling factors affect MICROSUL utilization?

Quick answer: For mature generics-adjacent brands, utilization depends on labeling that supports tolerability narratives, consistent product supply, and administrative ease (NDC availability, substitution status).

Substitution and pharmacy billing

• whether MICROSUL is considered substitutable under state pharmacy rules
• claim adjudication outcomes tied to NDC-level billing rules

Safety and tolerability

Sulfonamide class tolerability affects adherence and persistence. If micronization reduces GI events in real-world use, it can drive improved persistence and lower discontinuation.

What patent litigation and settlements would change the MICROSUL outlook?

Quick answer: Litigation would matter only if MICROSUL’s Orange Book-listed patents remain active and are strong enough to produce a launch delay or meaningful settlement protection. Without a provable patent moat, settlements typically do not create sustained pricing power.

Commercial impact of typical litigation outcomes

• Dismissal/invalidity: accelerates generic erosion through earlier approvals and launch
• Infringement/settlement with launch delays: can temporarily defend net price and share
• No settlement: generic launches often proceed quickly post-adjudication

How much revenue exposure does MICROSUL face under different generic launch scenarios?

Quick answer: The revenue exposure is high under any scenario where MICROSUL loses preferred access or faces accelerated generic parity. Key exposure pathways:

• net price compression from rebate renegotiation
• TRx volume decline due to switching at the pharmacy level
• utilization shift to alternatives within UC/RA

Scenario framework (directional, business-planning oriented)

Scenario	What happens	Revenue outcome
Preferred access maintained	MICROSUL stays preferred or limited-step restricted	Stable or modest decline over time
Preferred access lost	PBM switches to cheaper generic NDCs	Sharp volume decline, margin compression
Legal/patent-driven delay (if any patents active)	Launch delay or settlement keeps competitor out	Short-term defense of share and price
Full competitive parity	Generic supply becomes default across plans	Long-run decline toward generic-level economics

Key Takeaways

• MICROSUL operates in a mature sulfasalazine market where generic substitution is the dominant long-run driver of price and volume.
• Micronization can support tolerability-based differentiation, but it does not typically create durable protection against generic price erosion.
• The financial trajectory is most sensitive to formulary access, rebate intensity, and substitution behavior rather than a single patent cliff.
• Any meaningful long-term economic moat requires active, enforceable differentiated IP reflected in Orange Book listings and sustained exclusivity.

FAQs

1) Is MICROSUL protected by Orange Book patents that delay generic entry?
Quick answer: Determine whether MICROSUL has active Orange Book-listed patents tied to the specific product/NDA. If listings are absent or near-expiry, generic entry pressure is immediate and primarily contract-driven.

2) Can payers treat micronized sulfasalazine as a distinct preferred product versus standard sulfasalazine?
Quick answer: Yes when PBM policies and clinical notes support a tolerability advantage at the NDC or product level. Otherwise, plans revert to lowest net cost within the sulfonamide class.

3) What is the biggest determinant of MICROSUL’s net revenue versus WAC?
Quick answer: Rebate and discount structure tied to PBM contracting and formulary position, which usually compresses WAC-to-net substantially for brands competing with generics.

4) How do UC and RA treatment guidelines affect MICROSUL demand over time?
Quick answer: Guideline shifts toward alternative 5-ASA or RA DMARD strategies can reduce sulfasalazine share, especially in mild-to-moderate segments where prescribers can choose newer or better-tolerated options.

5) What settlement terms most directly protect MICROSUL revenue?
Quick answer: Terms that include launch delays, supply-based restrictions, or cross-licenses tied to differentiated product attributes, paired with continued formulary placement.

References

1. FDA Orange Book: Approved Drug Products with Therapeutapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
2. Drugs@FDA. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/